Thomas O’Connell, MA
Mr. O’Connell’s experience spans the healthcare and consumer-technology industries. He has provided economic-consulting services addressing commercial/market-access strategies to various large pharmaceutical corporations, and has conducted economic analyses informing litigation between major Silicon Valley technology corporations.
In his healthcare work, Mr. O’Connell has focused on optimization of market-access/reimbursement strategy, and on economic evaluations for health-technology assessment (HTA). His models have been used by pharmaceutical corporations in establishing strategies concerning international reference pricing, foreign market access and reimbursement, and optimal launch-price and discounting strategies in the US. In support of products undergoing HTA (primarily for ultra-rare diseases), he has conducted cost-effectiveness and budget-impact analyses and/or authored technical reports for HTA submissions in 15+ markets. He has engaged in-person with HTA agencies in scoping/ committee meetings (including CADTH, NCPE, ZIN, and SMC), and served as the health-economics advisor in negotiations of a Managed Access Agreement (MAA) between a client and NICE/NHS England for an ultra-rare-disease product, which resulted in a “first of a kind” MAA providing access to therapy for pediatric-onset hypophosphatasia patients with severe unmet need in England. In addition, Mr. O’Connell has advised clients through review by the Institute for Clinical and Economic Review (ICER) in the US, and presented to cross-functional groups at client companies on HEOR theory and methods and their role in supporting market access.